NCT02262767 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Healthy

Interventions

DRUG

PF-06649751

Experimental Pfizer compound.

DRUG

Trimethobenzamide Hydrochloride

Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Trial Locations (2)

Belgium Pfizer Clinical Research Unit, Brussels

Pfizer Clinical Research Unit, Brussels